Market Intelligence for m6A Reader Protein Therapeutics and High-Purity Reagents for Epitranscriptomic Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for YTHDC2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YTHDC2 Recombinant Protein (YTH Domain / Full-Length). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. | View YTHDC2 Products |
| Gene Delivery | YTHDC2 Lentivirus Particles (Full-length ORF). Titer >10^8 TU/mL. Ideal for stable cell lines and PROTAC degradation assays. | View YTHDC2 Products |
| Benchmark Ab | Anti-YTHDC2 Monoclonal Antibody (Sequence-Defined). Recombinant positive control for Western, IF, and IP. | View YTHDC2 Products |
| Validator | YTHDC2 siRNA Set (3 unique sequences). For knockdown verification and off-target screening. HPLC purified. | View YTHDC2 Products |
| Epitranscriptomic Writer | METTL3 Recombinant Protein. m6A methyltransferase catalytic subunit for complementary mechanistic studies. | View METTL3 Products |
| Companion Reader | YTHDF2 Recombinant Protein. Competing m6A reader for selectivity screening and pathway cross-talk analysis. | View YTHDF2 Products |
| Reader Homolog | YTHDF1 Recombinant Protein. Critical for counter-screening and target selectivity assays. | View YTHDF1 Products |
| Eraser | FTO Recombinant Protein. m6A demethylase for dynamic pathway modulation and counter-screening. | View FTO Products |
| Alternative Reader | IGF2BP1 Recombinant Protein. Compensatory resistance mechanism via non-YTH m6A reading. | View IGF2BP1 Products |
| Paralog | YTHDC1 Recombinant Protein. Nuclear reader for cross-family selectivity profiling. | View YTHDC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| m6A-Binding Specificity Determination | YTH Domain Construct with validated RNA-binding fold, >95% purity by SEC-HPLC, Endotoxin <1EU/µg. RNase-free production. |
| Cross-Reader Selectivity (YTH Family) | Ortholog Panel available: YTHDC1, YTHDC2, YTHDF1-3; sequence-verified distinct binding pockets by mass spec. |
| Intracellular Mechanism Validation | High-titer Lentivirus Premade Particles for stable cell line construction; suitable for RNA immunoprecipitation (RIP) assays and CETSA. |
| Target Engagement Confirmation | Chemically synthesized siRNA with dTdT overhangs; sequence-specific knockdown verified by qPCR. |
| Specificity Controls (m6A-Binding Dead Mutants) | Engineered binding-deficient YTH domain mutant available; theoretical MW confirmed by SEC-HPLC for negative control in pulldown and SPR. |
| PROTAC Degradation Validation | Clinical Benchmark Antibodies included for precise endogenous degradation tracking; full-length protein for ternary complex formation. |
| False Positive Reduction in Hit-to-Lead | Validated siRNA included for genetic baseline specificity checks; RNase-free reagents prevent probe degradation. |
Live YTHDC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The YTHDC2 target represents a frontier in epitranscriptomic drug discovery. As an m6A "reader" protein possessing unique RNA helicase activity (DEAD-box domain), YTHDC2 has emerged as a critical driver in tumor progression, metastasis, and cancer stem cell maintenance. Unlike the more extensively studied YTHDF proteins, YTHDC2's nuclear localization and specific interaction with the nuclear exosome targeting (NEXT) complex present unique therapeutic opportunities in solid tumors and viral pathogenesis. The current R&D landscape is dominated by early-stage discovery programs and academic consortia exploring small-molecule disruption of the YTHDC2–m6A interaction. Major early-stage biotechs and academic spin-offs are shifting focus from simply validating m6A "writers" (like METTL3) to targeting the "readers" that execute the downstream oncogenic translation. As first-generation RNA-modifying therapies reach clinical evaluation, the next wave of development is expected to focus on proteolysis-targeting chimeras (PROTACs) and molecular glues that selectively degrade YTHDC2 in refractory tumor settings. Combination strategies with immune checkpoint modulators and METTL3 inhibitors are emerging, driven by the crosstalk between m6A pathways and tumor immune microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Early-stage Biotechs / Academia | Solid Tumors, AML | Selectivity Assay: high-purity WT vs. homolog proteins for SPR/BLI/AlphaScreen; m6A-RNA binding competition. |
| PROTAC (Degrader) | Epitranscriptomic Startups | Refractory Cancers | Degradation Validation: full-length YTHDC2 protein, sequence-verified antibodies, stable lentivirus cells for DC50/Dmax. |
| ASO (Antisense Oligonucleotides) | Academic Consortia | Solid Tumors, Viral Infections | Specificity assays using YTHDC2 recombinant protein; off-target YTH family screening. |
| Molecular Glues | TPD-focused Biotechs | Proteinopathy | Cell-based target engagement using Lentivirus-expressed YTHDC2; ternary complex formation. |
| Epigenetic Editing | CRISPR Platform Companies | Immunotherapy | Rescue experiments using siRNA-resistant YTHDC2 mutants; dCas13-fused m6A editing. |
| RNAi / Genetic Modality | Research-stage Programs | HCC, Glioblastoma | Knockdown verification with validated siRNA and benchmark antibodies. |
Molecular Features & Key Mutations
YTHDC2 (UniProt Q9H6S0) contains functional domains: R3H domain (RNA binding), Helicase ATP-binding domain, and Helicase C-terminal domain. Known coding variants include dbSNP:rs10071816 and dbSNP:rs1132528, which may influence protein function. These features are essential for target validation and assay design, particularly in selectivity and mutant control studies.